构建和临床应用基于N6-甲基氨酸调节剂的结直肠癌风险模型
Hanhan Zhu1, Yu Yang1, Zhenfeng Zhou2
1Oncology Department, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.
PeerJ
|December 24, 2024
概括
这项研究开发了基于N6-甲基氨酸 (m6A) 调节器的风险评分,以预测结直肠癌 (CRC) 的预后. 该模型有效地区分高风险患者的不良结果,有助于CRC诊断和管理.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 大肠直肠癌 (CRC) 是发达国家普遍存在的恶性瘤.
- N6-甲基氨酸 (m6A) 调节剂在CRC进展中发挥作用.
- 建立预后签名对于CRC管理至关重要.
研究的目的:
- 开发基于m6A调节器的结直肠癌 (CRC) 的预后特征.
- 确定关键的m6A调节器及其与CRC患者结果的关联.
- 探索CRC中潜在的治疗点和免疫透.
主要方法:
- 使用了来自公共数据库 (AC-ICAM,GSE33113,GSE146771) 的大量和单细胞RNA测序数据.
- 进行了共识聚类,基因组丰富分析 (GSEA) 和 LASSO 考克斯回归来构建风险模型.
- 进行了体外测试 (qPCR,伤口愈合,transwell) 并分析了免疫细胞透和药物敏感性.
主要成果:
- 根据九个m6A调节器,确定了三种CRC分子亚型.
- 使用METTL3,IGF2BP3和YTHDC2开发了一个风险评分,有效地将患者分为高风险和低风险组.
- 高风险患者的预后较差,免疫细胞透率增加,炎症途径激活. 抑制METTL3或IGF2BP3可以减少CRC细胞的入侵和迁移.
- 为临床应用开发了一种名录,并确定了八种潜在药物.
结论:
- 基于m6A调节器的风险评分是结直肠癌 (CRC) 发展和患者预后的关键预测指标.
- 这种模型可以显著帮助诊断和临床管理的CRC患者.
- 研究结果提供了关于m6A修饰在CRC中的作用和潜在的治疗策略的见解.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...